• 1
    Parkin DM,Bray F,Ferlay J,Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74108.
  • 2
    Jemal A,Siegel R,Ward E,Hao Y,Xu J,Murray T,Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 4366.
  • 3
    Lippman SM,Sudbo J,Hong WK. Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol 2005; 23: 34656.
  • 4
    Forastiere A,Koch W,Trotti A,Sidransky D. Head and neck cancer. N Engl J Med 2001; 345: 1890900.
  • 5
    Gourin C,Podolsky R. Racial disparities in patients with head and neck squamous cell carcinoma. Laryngoscope 2006; 116: 1093106.
  • 6
    Lin DT,Subbaramaiah K,Shah J,Dannenberg AJ,Boyle JO. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 2002; 24: 7929.
  • 7
    Kelloff G,Lippman SM,Dannenberg AJ,Sigman CC,Pearce HL,Reid BJ,Szabo E,Jordan VC,Spitz MR,Mills GB,Papadimitrakopoulou VA,Lotan R, et al. AACR Task Force on Cancer Prevention. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer—a plan to move forward. Clin Cancer Res 2006; 12: 366197.
  • 8
    Gu X,Song X,Dong Y,Cai H,Walters E,Zhang R,Pang X,Xie T,Guo Y,Sridhar R,Califano JA. Vitamin E succinate induces ceramide-mediated apoptosis in human head and neck squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 2008; 14: 18408.
  • 9
    Wang Z. The role of COX-2 in oral cancer development, and chemoprevention/treatment of oral cancer by selective COX-2 inhibitors. Curr Pharm Des 2005; 11: 17717.
  • 10
    Moraitis D,Du B,De Lorenzo MS,Boyle JO,Weksler BB,Cohen EG,Carew JF,Altorki NK,Kopelovich L,Subbaramaiah K,Dannenberg AJ. Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res 2005; 65: 66470.
  • 11
    Li N,Sood S,Wang S,Fang M,Wang P,Sun Z,Yang CS,Chen X. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin Cancer Res 2005; 11: 208996.
  • 12
    Bergmann C,Strauss L,Zeidler R,Lang S,Whiteside TL. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 2007; 67: 886573.
  • 13
    Chang HW,Roh JL,Jeong EJ,Lee SW,Kim SW,Choi SH,Park SK,Kim SY. Wnt signaling controls radiosensitivity via cyclooxygenase-2-mediated Ku expression in head and neck cancer. Int J Cancer 2008; 122: 1007.
  • 14
    Gross ND,Boyle JO,Morrow JD,Williams MK,Moskowitz CS,Subbaramaiah K,Dannenberg AJ,Duffield-Lillico AJ. Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers. Clin Cancer Res 2005; 11: 608793.
  • 15
    Schuon R,Brieger J,Franke RL,Jakob R,Mann WJ. Increased PGE2 levels in nonmalignant mucosa adjacent to squamous cell carcinoma of the head and neck. ORL J Otorhinolaryngol Relat Spec 2005; 67: 96100.
  • 16
    Chang MC,Wu HL,Lee JJ,Lee PH,Chang HH,Hahn LJ,Lin BR,Chen YJ,Jeng JH. The induction of prostaglandin E2 production, interleukin-6 production, cell cycle arrest, and cytotoxicity in primary oral keratinocytes and KB cancer cells by areca nut ingredients is differentially regulated by MEK/ERK activation. J Biol Chem 2004; 279: 5067683.
  • 17
    Zhang DY,Wu J,Ye F,Xue L,Jiang S,Yi J,Zhang W,Wei H,Sung M,Wang W,Li X. Inhibition of cancer cell proliferation and prostaglandin E2 synthesis by Scutellaria baicalensis. Cancer Res 2003; 63: 403743.
  • 18
    Bertagnolli MM,Eagle CJ,Zauber AG,Redston M,Solomon SD,Kim K,Tang J,Rosenstein RB,Wittes J,Corle D,Hess TM,Woloj GM, et al;APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355: 87384.
  • 19
    Arber N,Eagle CJ,Spicak J,Rácz I,Dite P,Hajer J,Zavoral M,Lechuga MJ,Gerletti P,Tang J,Rosenstein RB,Macdonald K, et al;PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355: 88595.
  • 20
    Nelson N. Years of research come to fruition with launch of oral cancer prevention trial. J Nat Cancer Inst 2006; 98: 889.
  • 21
    Patel MI,Subbaramaiah K,Du B,Chang M,Yang P,Newman RA,Cordon-Cardo C,Thaler HT,Dannenberg AJ. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005; 11: 19992007.
  • 22
    Solomon SD,McMurray J,Pfeffer M,Wittes J,Fowler R,Finn P,Anderson WF,Zauber A,Hawk E,Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 107180.
  • 23
    Walters R.Chinese medicine and cancer, vol. 239. 2006. 28191. ( Excerpted with permission from Walters R. Options: The Alternative Cancer Therapy Book, Garden City Park, New York: Avery Publishing Inc., 1993).
  • 24
    Wu J. An illustrated Chinese Materia Medica. Oxford University Press, 2005. 706.
  • 25
    Wang X,Morris-Natschke SL,Lee KH. New developments in the chemistry and biology of the bioactive constituents of Tanshen. Med Res Rev 2007; 27: 13348.
  • 26
    HuangKC, ed. The pharmacology of Chinese herbs. CRC publishers, 1992. 388.
  • 27
    National Pharmacopoeia Council of China. Chinese Pharmacopoeia, Part I, 2005 edition. Beijing: Chemical Industry Publishing Company, 2005. 52 p.
  • 28
    Hu P,Luo GA,Zhao Z,Jiang ZH. Quality assessment of radix Salviaemiltiorrhizae. Chem Pharm Bull 2005; 53: 4816.
  • 29
    Zhu H,Xie T,Gu X,Ji H,Yang Y,Ge M,Song X,Xue J. Antitumor effect of salvianolic aid B. Chin J Practical Med 2004; 4: 22246.
  • 30
    Zhou ZT,Yang Y,Ge JP. The preventive effect of salvianolic acid B on malignant transformation of DMBA-induced oral premalignant lesion in hamsters. Carcinogenesis 2006; 27: 82632.
  • 31
    Efferth T,Kahl S,Paulus K,Adams M,Rauh R,Boechzelt H,Hao X,Kaina B,Bauer R. Phytochemistry and pharmacogenomics of natural products derived from traditional Chinese medicine and Chinese materia medica with activity against tumor cells. Mol Cancer Ther 2008; 7: 15261.
  • 32
    Chen YH,Lin SJ,Chen YL,Liu PL,Chen JW. Anti-inflammatory effects of different drugs/agents with antioxidant property on endothelial expression of adhesion molecules. Cardiovasc Hematol Disord Drug Targets 2006; 6: 279304.
  • 33
    Liu CS,Cheng Y,Hu JF,Zhang W,Chen NH,Zhang JT. Comparison of antioxidant activities between salvianolic acid B and Ginkgo biloba extract (EGb 761). Acta Pharmacol Sin 2006; 27: 113745.
  • 34
    Zhu YZ,Huang SH,Tan BK,Sun J,Whiteman M,Zhu YC. Antioxidants in Chinese herbal medicines: a biochemical perspective. Nat Prod Rep 2004; 21: 47889.
  • 35
    Chen YL,Hu CS,Lin FY,Chen YH,Sheu LM,Ku HH,Shiao MS,Chen JW,Lin SJ. Salvianolic acid B attenuates cyclooxygenase-2 expression in vitro in LPS-treated human aortic smooth muscle cells and in vivo in the apolipoprotein-E-deficient mouse aorta. J Cell Biochem 2006; 98: 61831.
  • 36
    Hollingshead MG,Alley MC,Camalier RF,Abbott BJ,Mayo JG,Malspeis L,Grever MR. In vivo cultivation of tumor cells in hollow fibers. Life. Sci. 1995; 57: 13141.
  • 37
    Adhami VM,Malik A,Zaman N,Sarfaraz S,Siddiqui IA,Syed DN,Afaq F,Pasha FS,Saleem M,Mukhtar H. Combined inhibitory effects of green tea polyphenols and selective cycloxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2007; 13: 16119.
  • 38
    Livak KJ,Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 2001; 25: 4028.
  • 39
    De Marzo AM,Platz EA,Sutcliffe S,Xu J,Grönberg H,Drake CG,Nakai Y,Isaacs WB,Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 25669.
  • 40
    Kelloff G,Sigman C. Assessing intraepithelial neoplasia and drug safety in cancer-preventive drug development. Nat Rev Cancer 2007; 7: 50818.
  • 41
    Steinbach G,Lynch P,Phillips RK,Wallace MH,Hawk E,Gordon GB,Wakabayashi N,Saunders B,Shen Y,Fujimura T,Su LK,Levin B, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 194652.
  • 42
    Kosaka T,Fukaya K,Tsuboi S,Pu H,Ohno T,Tsuji T,Namba M. Comparison of various methods of assaying the cytotoxic effects of ethanol on human hepatoblastoma cells (HUH-6 line). Acta Med Okayama 1996; 50: 1516.
  • 43
    Tsujii M,DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493501.
  • 44
    The State Pharmacopoeia Commission of People's Republic of China. The People's Republic of China Pharmacopoeia, 2005, vol. I. Beijing: Chemical Industry Press, 2005. 394.
  • 45
    Yang J,Gui C,Xiong Y,Chen G,Ding B,Song J. Study on acute and topical toxicity of Danshen glucose injection. Acta Academiae Mediciae Wannan 2007; 1: 113.
  • 46
    Han J,Liu X,Xu Y,Wang W,Ma Z,Xiong Y. Long-term toxicity study of Salviamiltiorrhiza glucose injection in rats. Acta Academiae Mediciae Wannan 2005; 4: 24852.